Literature DB >> 24690510

Insulin infusion therapy in critically ill patients.

Jean-Marie Boutin1, Lyne Gauthier2.   

Abstract

While dysglycemia (hyperglycemia, hypoglycemia and glucose variability) is clearly associated with increased mortality in critically ill patients, target range of blood glucose control remains controversial. Standardized insulin infusion protocols constitute the basis of treatment of these patients. The choice of protocol and its implementation is a great challenge. In this article, we review the published data to help define the essential elements that compose a good protocol and apply the right conditions to make it safe and effective.
Copyright © 2014 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  computer-base protocol; critical care; hyperglycemia; hyperglycémie; intravenous insulin protocol; protocole d'insuline par voie intraveineuse; protocole informatisé; soins aux patients gravement atteints

Mesh:

Substances:

Year:  2014        PMID: 24690510     DOI: 10.1016/j.jcjd.2014.01.016

Source DB:  PubMed          Journal:  Can J Diabetes        ISSN: 1499-2671            Impact factor:   4.190


  3 in total

Review 1.  Transitioning safely from intravenous to subcutaneous insulin.

Authors:  Kathryn Evans Kreider; Lillian F Lien
Journal:  Curr Diab Rep       Date:  2015-05       Impact factor: 4.810

2.  Blood glucose control using a computer-guided glucose management system in allogeneic hematopoietic cell transplant recipients.

Authors:  C Espina; I Jenkins; L Taylor; R Farah; E Cho; J Epworth; K Coleman; J Pinelli; S Mentzer; L Jarrett; T Gooley; P O'Donnell; I B Hirsch; M Bar
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

3.  A comparison of two insulin infusion protocols in the medical intensive care unit by continuous glucose monitoring.

Authors:  Christophe E M De Block; Peter Rogiers; Philippe G Jorens; Tom Schepens; Cosimo Scuffi; Luc F Van Gaal
Journal:  Ann Intensive Care       Date:  2016-11-22       Impact factor: 6.925

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.